Journal of the American Academy of Dermatology
Comment on "Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network" by Katherine Benandi et al.
Ya-An Tsai
Published: 202510.1016/j.jaad.2025.10.165
No abstract available for this study.